Reducing malaria morbidity in infants through perennial malaria chemoprevention in Nigeria
Published:
Resources: Project brief
The PMC Effect study is assessing the clinical effectiveness and operational feasibility of perennial malaria chemoprevention (PMC) with the aim of supporting its uptake into national policy and scale-up across Nigeria.
To reduce malaria morbidity and mortality in infants, the World Health Organization (WHO) recommends perennial malaria chemoprevention (PMC) with sulfadoxine-pyrimethamine in areas with moderate to high malaria transmission, and where transmission occurs throughout the year. WHO's updated guidelines allow for greater flexibility on the number and frequency of antimalarial doses given and the ages of children who receive them. However, barriers to PMC policy uptake remain. This study will assess PMC’s clinical effectiveness and operational feasibility in Nigeria. It aims to generate the necessary evidence to support the intervention’s uptake in the national health policy.
